相似文献
1
Influence of liposomal amphotericin B on CD8 T-cell function.
Antimicrob Agents Chemother. 2001 Aug;45(8):2383-5. doi: 10.1128/AAC.45.8.2383-2385.2001.
2
Suppression of acquired immunity against Listeria monocytogenes by amphotericin B-mediated inhibition of CD8 T cell function.
J Infect Dis. 1999 Oct;180(4):1186-94. doi: 10.1086/315007.
3
Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
J Antimicrob Chemother. 2006 Jul;58(1):125-32. doi: 10.1093/jac/dkl177. Epub 2006 May 18.
4
Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
J Antimicrob Chemother. 2005 Oct;56(4):726-31. doi: 10.1093/jac/dki307. Epub 2005 Aug 26.
5
Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
J Antimicrob Chemother. 2005 Feb;55(2):214-22. doi: 10.1093/jac/dkh542. Epub 2005 Jan 13.
6
Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
J Pharm Pharm Sci. 2003 May-Aug;6(2):231-7.
7
[Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Dtsch Med Wochenschr. 2007 Oct;132(40):2062-6. doi: 10.1055/s-2007-985641.
8
Use of liposomal amphotericin B in bone marrow transplant.
J Postgrad Med. 2005;51 Suppl 1:S49-52.
9
Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Antimicrob Agents Chemother. 2005 Dec;49(12):4895-902. doi: 10.1128/AAC.49.12.4895-4902.2005.
10
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.
Diagn Microbiol Infect Dis. 2004 Dec;50(4):247-51. doi: 10.1016/j.diagmicrobio.2004.07.011.
引用本文的文献
1
CD4 Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis.
Front Immunol. 2024 Feb 12;15:1277557. doi: 10.3389/fimmu.2024.1277557. eCollection 2024.
2
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis.
Wellcome Open Res. 2019 Dec 10;4:198. doi: 10.12688/wellcomeopenres.15606.1. eCollection 2019.
3
Antifungal Drugs Influence Neutrophil Effector Functions.
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.02409-18. Print 2019 Jun.
4
Impact of Antifungal Compounds on Viability and Anti- Activity of Human Natural Killer Cells.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01993-18. Print 2019 Feb.
5
Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.
Front Oncol. 2013 Feb 7;3:17. doi: 10.3389/fonc.2013.00017. eCollection 2013.
6
Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis in late adulthood.
Am J Trop Med Hyg. 2013 Mar;88(3):575-7. doi: 10.4269/ajtmh.12-0563. Epub 2013 Jan 16.
7
Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation.
Antimicrob Agents Chemother. 2003 Jun;47(6):1818-23. doi: 10.1128/AAC.47.6.1818-1823.2003.
本文引用的文献
1
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.
Clin Infect Dis. 2000 Apr;30(4):696-709. doi: 10.1086/313756. Epub 2000 Apr 20.
2
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
Clin Infect Dis. 2000 Apr;30(4):662-78. doi: 10.1086/313749. Epub 2000 Apr 20.
3
Suppression of acquired immunity against Listeria monocytogenes by amphotericin B-mediated inhibition of CD8 T cell function.
J Infect Dis. 1999 Oct;180(4):1186-94. doi: 10.1086/315007.
4
Enhancement of the Listeria monocytogenes p60-specific CD4 and CD8 T cell memory by nonpathogenic Listeria innocua.
J Immunol. 1999 Apr 15;162(8):4781-9.
5
Lipid formulations of amphotericin B: clinical efficacy and toxicities.
Clin Infect Dis. 1998 Sep;27(3):603-18. doi: 10.1086/514704.
6
Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Drugs. 1998 Apr;55(4):585-612. doi: 10.2165/00003495-199855040-00008.
7
Murine listeriosis as a model of antimicrobial defense.
Immunol Rev. 1997 Aug;158:27-36. doi: 10.1111/j.1600-065x.1997.tb00989.x.
8
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.
Clin Infect Dis. 1997 Jul;25(1):43-59. doi: 10.1086/514504.
9
Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Arzneimittelforschung. 1996 Jul;46(7):711-5.
10
Lipid formulations of amphotericin B: recent progress and future directions.
Clin Infect Dis. 1996 May;22 Suppl 2:S133-44. doi: 10.1093/clinids/22.supplement_2.s133.
Zotero 插件